Great Ormond Street Hospital’s response to guidance on the use of cannabis-based products for medicinal use in children and young people with epilepsy

21 Jan 2019, 4:53 p.m.

Great Ormond Street Hospital Trust logo 2018

As a neurology consultant group at GOSH we welcome the publication of the “Guidance on the use of cannabis‐based products for medicinal use in children and young people with epilepsy” by the British Paediatric Neurology Association (BPNA), it is positive to have this framework in place.

In accordance with this policy document we consider only purified Cannabidiol for patients with very difficult to treat epilepsy, who are not candidates for epilepsy surgery, vagus nerve stimulation treatment or the ketogenic diet.

Currently we are awaiting further guidance from NICE and NHS England that will address questions of funding and prescription for patients. In general, purified Cannabidiol is not available for prescription apart from in a very few limited cases where expert clinicians deem it suitable.

Please note the guidance note above is the very latest and supersedes the previous press release we issued on 31 October 2018 - see historic press release on GOSH website.